论文部分内容阅读
目的采用中药加味寿胎胶囊对乙肝免疫耐受患者口服干预,检测干预前后血清中肿瘤坏死因子(TNF-α)表达水平,研究TNF-α与乙肝免疫耐受是否存在相关性,探讨加味寿胎胶囊打破乙肝免疫耐受的机制。方法对60份乙肝免疫耐受患者治疗前后及20例健康体检者血清标本采用ELISA方法作TNF-α检测,生化仪行肝功能检查,对结果相关性加以分析。结果治疗前乙肝免疫耐受患者血清TNF-α阳性率为9%,治疗后39例患者免疫耐受突破,血清TNF-α阳性率为60%。结论 TNF-α和乙肝免疫耐受具有相关性;ALT、TNF-α可以间接反映乙肝免疫耐受突破情况,及时检测ALT、TNF-α可以适时进行抗病毒治疗;加味寿胎胶囊具有突破乙肝免疫耐受作用。
Objective To investigate the effects of modified Tanshou Capsule on the immune tolerance of Hepatitis B patients before and after intervention. The levels of tumor necrosis factor (TNF-α) in serum were detected before and after intervention. The correlation between TNF-α and immune tolerance of hepatitis B Capsules break the mechanism of hepatitis B immune tolerance. Methods Serum samples of 60 hepatitis B immune tolerance patients before and after treatment and 20 healthy subjects were detected by ELISA for the detection of TNF-α, and the biochemical analyzer was used to check the liver function. The correlation of the results was analyzed. Results Before treatment, the positive rate of serum TNF-α in patients with hepatitis B immune tolerance was 9%. After the treatment, 39 patients had a breakthrough in immune tolerance. The positive rate of serum TNF-α was 60%. Conclusion TNF-α and hepatitis B immune tolerance are correlated; ALT, TNF-αcan indirectly reflect the breakthrough of immune tolerance of hepatitis B, detect ALT in time and TNF-αcan be timely antiviral treatment; Tolerance.